HLS Therapeutics Toekomstige groei
Future criteriumcontroles 0/6
De verwachting is dat HLS Therapeutics de winst en omzet met respectievelijk 10.3% en 3.7% per jaar zal laten groeien, terwijl de winst per aandeel naar verwachting zal groeien met 12.3% per jaar.
Belangrijke informatie
71.5%
Groei van de winst
67.9%
Groei van de winst per aandeel
Pharmaceuticals winstgroei | 54.5% |
Inkomstengroei | 7.0% |
Toekomstig rendement op eigen vermogen | n/a |
Dekking van analisten | Low |
Laatst bijgewerkt | 18 Oct 2024 |
Recente toekomstige groei-updates
Recent updates
Are Investors Undervaluing HLS Therapeutics Inc. (TSE:HLS) By 45%?
Oct 26Pinning Down HLS Therapeutics Inc.'s (TSE:HLS) P/S Is Difficult Right Now
Sep 28Analysts Have Lowered Expectations For HLS Therapeutics Inc. (TSE:HLS) After Its Latest Results
May 12After Leaping 29% HLS Therapeutics Inc. (TSE:HLS) Shares Are Not Flying Under The Radar
Apr 14Here's Why HLS Therapeutics (TSE:HLS) Can Afford Some Debt
Apr 06Analysts Are More Bearish On HLS Therapeutics Inc. (TSE:HLS) Than They Used To Be
Nov 16Here's Why HLS Therapeutics (TSE:HLS) Can Afford Some Debt
Sep 13Would HLS Therapeutics (TSE:HLS) Be Better Off With Less Debt?
May 05HLS Therapeutics (TSE:HLS) Is Due To Pay A Dividend Of $0.05
Apr 05HLS Therapeutics (TSE:HLS) Is Paying Out A Dividend Of $0.05
Mar 20HLS Therapeutics (TSE:HLS) Has Affirmed Its Dividend Of $0.05
Nov 30Downgrade: Here's How Analysts See HLS Therapeutics Inc. (TSE:HLS) Performing In The Near Term
Nov 11We Think HLS Therapeutics (TSE:HLS) Has A Fair Chunk Of Debt
Sep 14HLS Therapeutics (TSE:HLS) Is Due To Pay A Dividend Of $0.05
Aug 15HLS Therapeutics (TSE:HLS) Is Due To Pay A Dividend Of $0.05
Jul 14HLS Therapeutics (TSE:HLS) Has Announced A Dividend Of CA$0.05
Jun 23HLS Therapeutics' (TSE:HLS) Dividend Will Be CA$0.05
Jun 08HLS Therapeutics' (TSE:HLS) Dividend Will Be CA$0.05
May 25HLS Therapeutics' (TSE:HLS) Dividend Will Be CA$0.05
May 10Time To Worry? Analysts Are Downgrading Their HLS Therapeutics Inc. (TSE:HLS) Outlook
Apr 30HLS Therapeutics (TSE:HLS) Has Affirmed Its Dividend Of CA$0.05
Apr 15HLS Therapeutics (TSE:HLS) Has Re-Affirmed Its Dividend Of CA$0.05
Mar 26HLS Therapeutics Inc. (TSE:HLS) Analysts Just Slashed This Year's Estimates
Mar 22HLS Therapeutics (TSE:HLS) Will Pay A Dividend Of CA$0.05
Nov 29Winst- en omzetgroeiprognoses
Datum | Inkomsten | Inkomsten | Vrije kasstroom | Geldmiddelen uit operationele activiteiten | Gem. Aantal analisten |
---|---|---|---|---|---|
12/31/2025 | 65 | -7 | N/A | N/A | 3 |
12/31/2024 | 58 | -16 | 7 | 7 | 4 |
6/30/2024 | 59 | -24 | 12 | 12 | N/A |
3/31/2024 | 61 | -28 | 12 | 13 | N/A |
12/31/2023 | 63 | -28 | 16 | 16 | N/A |
9/30/2023 | 63 | -29 | 15 | 16 | N/A |
6/30/2023 | 63 | -26 | 4 | 14 | N/A |
3/31/2023 | 62 | -26 | 5 | 15 | N/A |
12/31/2022 | 61 | -24 | 7 | 17 | N/A |
9/30/2022 | 61 | -21 | 7 | 17 | N/A |
6/30/2022 | 61 | -19 | 16 | 17 | N/A |
3/31/2022 | 60 | -12 | 12 | 15 | N/A |
12/31/2021 | 60 | -13 | 12 | 16 | N/A |
9/30/2021 | 61 | -16 | 11 | 18 | N/A |
6/30/2021 | 59 | -16 | -22 | 17 | N/A |
3/31/2021 | 57 | -20 | -28 | 11 | N/A |
12/31/2020 | 56 | -15 | -35 | 9 | N/A |
9/30/2020 | 54 | -20 | -41 | 6 | N/A |
6/30/2020 | 54 | -21 | -9 | 10 | N/A |
3/31/2020 | 55 | -16 | 4 | 23 | N/A |
12/31/2019 | 54 | -20 | 11 | 26 | N/A |
9/30/2019 | 57 | -7 | 11 | 35 | N/A |
6/30/2019 | 59 | -25 | 22 | 35 | N/A |
3/31/2019 | 61 | -24 | 14 | 28 | N/A |
12/31/2018 | 61 | -25 | 18 | 33 | N/A |
9/30/2018 | 65 | -26 | 28 | 30 | N/A |
6/30/2018 | 70 | -8 | 20 | 33 | N/A |
3/31/2018 | 73 | -8 | N/A | 37 | N/A |
12/31/2017 | 75 | -6 | N/A | 27 | N/A |
9/30/2017 | 71 | -11 | N/A | 25 | N/A |
12/31/2016 | 54 | -15 | N/A | 22 | N/A |
12/31/2015 | 20 | -10 | N/A | -6 | N/A |
Toekomstige groeivoorspellingen analisten
Verdiensten versus spaarpercentage: De verwachting is dat HLS de komende 3 jaar verliesgevend zal blijven.
Winst versus markt: De verwachting is dat HLS de komende 3 jaar verliesgevend zal blijven.
Hoge groeiwinsten: De verwachting is dat HLS de komende 3 jaar verliesgevend zal blijven.
Omzet versus markt: De omzet van HLS ( 3.7% per jaar) zal naar verwachting langzamer groeien dan de markt Canadian ( 7% per jaar).
Hoge groei-inkomsten: De omzet van HLS ( 3.7% per jaar) zal naar verwachting langzamer groeien dan 20% per jaar.
Groeiprognoses winst per aandeel
Toekomstig rendement op eigen vermogen
Toekomstige ROE: Onvoldoende gegevens om te bepalen of het rendement op eigen vermogen van HLS naar verwachting over 3 jaar hoog zal zijn